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Abstract 
Diethylenetriaminepentaacetic acid (DTPA) is a useful chelating agent for radionuclides such as 
68Ga, 99mTc and 111In, which are applicable to nuclear medicine imaging. In this study, we 
established a facile synthetic protocol for the production of mono-DTPA-conjugated peptide probes. 
A novel monoreactive DTPA precursor reagent was synthesized in two steps using the chemistry of 
the o-nitrobenzenesulfonyl (Ns) protecting group, and under mild conditions this DTPA precursor 
was incorporated onto an Nε-bromoacetylated Lys of a protected peptide resin. The site-specific 
DTPA conjugation was facilitated by using a highly acid-labile 4-methyltrityl (Mtt) protecting 
group for the target site of the bioactive peptide during the solid-phase synthesis. A combination of 
both techniques yielded peptides with disulfide bonds, such as octreotide and polyphemusin 
II-derived CXCR4 antagonists. DTPA-peptide conjugates were purified in a single step following 
cleavage from the resin and disulfide bond formation. This site-specific on-resin construction 
strategy was used for the design and synthesis of a novel In-DTPA-labeled CXCR4 antagonist, 
which exhibited highly potent inhibitory activity against SDF-1–CXCR4 binding. 
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1. Introduction 
Recent progress in molecular imaging methodologies such as positron emission tomography 
(PET), single-photon emission computed tomography (SPECT) and optical imaging technologies 
has significantly improved the early detection and diagnosis of malignant tumors. To visualize the 
specific molecular events involved in the physiological and/or pathological processes, a number of 
peptide-based imaging probes have been developed for overexpressed receptors of peptide 
hormones and extracellular matrix proteins.1 These probes are usually designed by a combination of 
three components: a target-specific vector peptide, an imaging part such as a radionuclide or 
fluorophore, and a linker to covalently or noncovalently conjugate the peptide with the imaging 
moiety. The addition of a functional moiety onto small-sized bioactive peptides may be highly 
susceptible to interaction with receptors or counterpart molecules. Consequently, there have been 
many reagents of choice for appropriate protein/peptide modifications. In addition, to determine the 
best labeling position from structure-function relationship studies, versatile synthetic approaches 
toward various types of labeled peptide are desired. 
Polyamino polycarboxylate ligands efficiently coordinate metal radioisotopes to aid the 
radiolabeling of bioactive peptides. Among the chelating ligands, 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 1a has been most widely utilized, 
since a variety of metal radioisotopes for both diagnostic and therapeutic purposes form complexes 
with high affinity and kinetic stability (Fig. 1).2 DOTA-modification of bioactive peptides is 
facilitated by commercially available reagents such as DOTA-NHS 1b and DOTA-maleimide 1c to 
provide the expected peptides in a single step.3,4 Alternatively, tris(tert-butyl)-DOTA 2a with a free 
carboxyl group is employed for the modification of an amino group of protected peptides bound to 
solid-supports.5 Lysine or phenylalanine derivatives 2b,c possessing a tert-butyl-protected DOTA 
moiety are also useful components for the peptide sequence assembly.6 tert-Butyl protecting groups 
in these reagents are easily removed during the final side-chain deprotection process of peptide 
synthesis. 
In contrast to these DOTA derivatives, there has been limited work exploring the application of 
the diethylenetriaminepentaacetic acid (DTPA) chelating group 3a, although DTPA represents a 
promising alternative, especially for 68Ga, 99mTc and 111In (Fig. 1). The recent success of 
DTPA-based probes is exemplified by a glucagon-like peptide-1 (GLP-1) receptor ligand, 
[Lys40(Ahx-DTPA-111In)NH2]-exendin-4, for insulinoma diagnosis.7 The DTPA group also works 
as a more favorable functional group than DOTA to facilitate the biological or biodistribution 
properties of several probes.8 For the preparation of DTPA-conjugated imaging probes, several 
conjugation reagents have been developed. The most familiar cyclic diethylenetriaminepentaacetic 
dianhydride 4 is a bifunctional chelating agent, which can conjugate with peptide hormones and 
antibodies.9 Using this reagent, concomitant formations of a bis-conjugated product10 and intra- and 
intermolecular cross-linked products11 were unavoidable. Monoreactive DTPA derivatives have 
also been developed for the preparation of DTPA-peptide conjugates without the unfavorable 
by-product formations.12,13 For example, we reported the synthesis and application of 
3,6,9,9-tetrakis[(tert-butoxycarbonyl)methyl]-3,6,9-triazanonanoic acid 3b (mDTPA),14 in which 
the four carboxylates were protected with tert-butyl ester. However, a longer process from the 
commercially available reagents is required for the synthesis of these DTPA-conjugation reagents 
(Scheme 1a). 
Accordingly, to establish a facile and efficient synthetic method for DTPA-peptide conjugates, 
we have investigated the site-specific and on-resin construction of a DTPA moiety. Herein, we 
describe the short-step synthesis of a DTPA precursor using the o-nitrobenzenesulfonyl (Ns) 
protecting group and the solid-phase synthesis of DTPA-peptide conjugates. The design and 
synthesis of DTPA-peptide conjugates that potentially target the somatostatin receptor and 
chemokine receptor CXCR4 are also presented.15  
 
2. Results and discussion 
2.1. Synthesis of a DTPA-conjugation reagent and the application to octreotide derivatives. 
The synthetic scheme for the production of mDTPA reagent 10, as described in our previous 
study, is presented in Scheme 1A. We hypothesized that two remedies could significantly improve 
the overall synthetic process of DTPA-peptide conjugates. First, the use of an Ns group in place of 
the trifluoroacetyl group was expected to serve as a temporary protecting group and an auxiliary 
group for global modification with four tert-butoxycarbonylmethyl groups. This potentially 
improves the stepwise synthesis of the intermediate 7 in the solution-phase. In addition, a secondary 
amine 8 as a nucleophilic precursor for the bromoacetyl group on peptide resin 11 can directly 
produce the overall DTPA framework of 12 on the solid support without the additional three-step 
modification process of 8 in solution (Scheme 1B).16 
Synthesis of DTPA precursor 8 began with mono-Ns protection of the commercially available 
diethylenetriamine 5 (Scheme 2). The Ns-protected intermediate was successively treated with 
excess equivalent of t-butyl bromoacetate in a one-pot process. Although the solvent EtOH has been 
reported to be effective in predominantly giving the mono-Ns product,17 concomitant production of 
bis-Ns product 14b was not suppressed as in DMF. The treatment of excess diethylenetriamine 5 
with NsCl in EtOH provided mono-Ns product 14a in 65% yield (calculated based on NsCl), which 
can be readily purified by chromatography. Compound 14a was then subjected to deprotection with 
mercaptoacetic acid and LiOH to provide the expected precursor 8 in 77% yield. 
Using the resulting reagent 8, DTPA-conjugation of [D-Phe1]octreotide was investigated as a 
model study (Scheme 3), which is employed as a radionuclide imaging probe for the somatostatin 
receptor.14,18,19 After peptide-chain elongation by Fmoc-based solid-phase peptide synthesis, the 
N-terminus of 16 was modified with bromoacetic acid and 1,3-diisopropylcarbodiimide (DIC). 
Subsequently, the bromide 17 was treated with the reagent 8 in the presence of (i-Pr)2NEt to 
provide the fully protected peptide resin 18a. Cleavage from the resin 18a and disulfide formation 
under air-oxidation conditions provided [DTPA-D-Phe1]octreotide 19a with high purity. The 
bromoacetylated peptide 17 was also modified with commercially available DOTA precursor 
reagent 20, using the identical procedure to provide [DOTA-D-Phe1]octreotide 19b.20 These suggest 
that this on-resin modification procedure is widely applicable to any chelating reagents with 
nucleophilic functional groups such as DTPA and DOTA precursors. 
 
2.2. Site-specific DTPA-conjugation of bioactive peptides: synthesis of CXCR4 receptor 
probes. 
It has been reported that a high level of CXCR4 expression in tumors is associated with 
malignant and metastatic properties.21 Intrinsic SDF-1 release from the potential distal metastatic 
sites mediates organ-specific metastasis of CXCR4-expressing cells from the primary lesions. Since 
CXCR4-expressing cancer stem cells are related to the metastatic spread in orthotopic primary 
tumors,22 it is of considerable importance to develop potent CXCR4-imaging probes to detect 
potential cancer stem cells within malignant tumors, as exemplified by the diagnosis of bladder 
cancer by a fluorescent CXCR4 probe.23,24 
Previously, we reported a DTPA-conjugated CXCR4 antagonist, DTPA-Ac-TZ14011 26a,25 
which was designed from a horseshoe crab-derived anti-HIV peptide T140. This peptide has 
β-sheet-like structures maintained by a disulfide bond, around which the pharmacophore residues 
for bioactivity are located.26 For the site-specific conjugation at D-Lys8 in the type II' β-turn region 
of T140 with a single DTPA group in the solution-phase, a secondary lysine (Lys7) was substituted 
with arginine, which cannot be acylated by standard reagents.25 Although a DTPA group was 
successfully ligated with maintenance of highly potent CXCR4 antagonistic activity in this case,25 
the accompanying substitutions needed for specific modification of other peptides may possibly 
lead to a decrease in the bioactivity. Therefore, we planned the facile site-specific DTPA 
conjugation on a solid-support for production of CXCR4 imaging probes without substitution of the 
secondary Lys7 residue. To distinguish D-Lys8 to be labeled in peptides 26, the highly acid-labile 
4-methyltrityl (Mtt) group was exploited for temporary protection of the ε-amino group during 
solid-phase peptide synthesis.27 For the other Lys residues such as Lys7 of 26b,c, a Boc group was 
employed. This group can be cleaved by the standard TFA-based treatment in Fmoc chemistry 
(Scheme 4). After the construction of the protected peptide resin, the orthogonal Mtt group at the 
labeling position was cleaved off using 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP). The resulting 
ε-amino group was successively modified with bromoacetic acid followed by the reagent 8 to 
provide the fully protected DTPA-peptide resin 25. Final deprotection, air-oxidation and HPLC 
purification afforded the expected DTPA-conjugated CXCR4 antagonists 26a,b. This concise 
protocol facilitates the selection of chelating structure and position(s) on the peptide chain, and aids 
structure-activity relationship studies aimed at exploring the more potent peptide probes. For 
example, a 4-fluorobenzoyl modification at the N-terminus, which should increase CXCR4 
antagonism,28 was easily appended to the peptide using this protocol to give the modified peptide 
26c. The subsequent treatment with nonradioactive InCl3 in acidic conditions provided the 
In-DTPA-labeled CXCR4 antagonists 27a-c.  
 
2.3. Bioactivity of In-DTPA-labeled CXCR4 antagonists. 
The biological activity of the In-DTPA-labeled peptides 27a-c was evaluated as the inhibitory 
potency of [125I]-SDF-1-binding to CXCR4 membrane extracts (Scheme 4). Peptides 27a,b, with an 
N-terminal acetyl group, exhibited similar potency towards CXCR4 [IC50(27a) = 1.95 ± 0.64 μM, 
IC50(27b) =  1.60 ± 0.91 μM], indicating that the Lys and Arg for the i-position of β-turn were 
both tolerant to the bioactivity. In contrast, peptide 27c exerted much more potent inhibitory activity 
for the SDF-1 binding to CXCR4 [IC50(27c) = 0.014 ± 0.010 μM]. These results of 
In-DTPA-labeled peptides 27a-c coincided with our previous report on the unlabeled peptides.28 
The novel potent In-DTPA-labeled CXCR4 antagonist 27c could be a promising imaging probe for 
CXCR4-expressing malignant cancer cells.11  
 
3. Conclusions 
In this study, we have established a novel synthetic method for the production of DTPA-peptide 
conjugates. The process includes facile solid-phase synthesis of a DTPA framework using a novel 
precursor substrate and site-specific conjugation using a highly acid-labile protecting group. Using 
a temporary Ns protecting group, the DTPA precursor 8 was obtained through two purification 
steps from commercially available diethylenetriamine. In addition, the on-resin incorporation of a 
bromoacetyl group into the specific free amino group followed by the addition of the nucleophilic 
DTPA precursors provided the expected DTPA-peptide conjugates with high purity. Taking 
advantage of secondary amine precursors of choice, these processes represent versatile methods to 
prepare a series of peptide conjugates, including DTPA and DOTA, for optimization of imaging 
probes. This conjugation method was applied to the preparation of DTPA-conjugates of octreotide 
and CXCR4 antagonist, which have been reported to effectively detect cancer cells. The peptide 27c 
with highly potent inhibitory activity of SDF-1 binding to CXCR4 was obtained without any amino 
acid substitution to avoid multiple modifications on the amino groups. This peptide represents a 




4.1.1. Bis(tert-butyl) 3,6-bis[(tert-butoxycarbonyl)methyl]-9-(o-nitrobenzenesulfonyl)-3,6,9- 
triazaundecanedioate (14a).  
To diethylenetriamine 5 (0.540 mL, 5.00 mmol) in dehydrated EtOH (5 mL), o-NsCl (0.367 g, 
1.67 mmol) was slowly added below 0 °C. After stirring for 2 h, EtOH was removed in vacuo. To 
dehydrated DMF (8 mL), K2CO3 (4.49 g, 32.5 mmol) and BrCH2CO2t-Bu (4.06 mL, 27.5 mmol) 
were added at 0 °C. The mixture was stirred overnight at room temperature, and filtered. The filtrate 
was concentrated under reduced pressure to give an oily residue, and the residue was dissolved in 
EtOAc (100 mL). The whole mixture was washed with saturated NaHCO3, and was dried over 
MgSO4. Concentration under reduced pressure followed by flash chromatography over silica gel 
with n-hexane–EtOAc gave compound 14a as a yellow oil (0.81 g, 65%); 1H NMR (CDCl3, 500 
MHz) δ 8.08–8.11 (1H, m), 7.64–7.69 (2H, m), 7.56–7.60 (1H, m), 4.24 (2H, s), 3.49 (2H, t, J = 6.9 
Hz), 3.42 (4H, s), 3.30 (2H, s), 2.88 (2H, t, J = 6.6 Hz), 2.78 (2H, t, J = 6.9 Hz), 2.77 (2H, t, J = 6.9 
Hz), 1.45 (27H, s), 1.36 (9H, s); 13C NMR (CDCl3, 500 MHz) δ 170.6 (3C), 168.0, 133.7, 133.2, 
131.6 (2C), 130.9, 123.9, 82.0, 81.0, 80.9 (2C), 56.1 (3C), 53.3, 52.8, 52.4, 49.4, 46.7, 28.1 (9C), 
27.9 (3C); HRMS (FAB) m/z calcd for C34H58N4O12S ([M+H]+): 746.3772, found 746.3779. 
4.1.2. Bis(tert-butyl) 3,6-bis[(tert-butoxycarbonyl)methyl]-3,6,9-triazaundecanedioate (8).  
To a solution of compound 14a (0.216 g, 0.29 mmol) in DMF (0.726 mL), LiOH (0.128 g, 2.90 
mmol) and mercaptoacetic acid (0.101 mL, 1.45 mmol) were added below 0 °C. After stirring for 2 
h at room temperature, the mixture was concentrated under reduced pressure, and the residue was 
dissolved in CHCl3. The whole reaction mixture was washed with saturated NaHCO3, and was dried 
over Na2SO4. Concentration under reduced pressure followed by flash chromatography over silica 
gel with CHCl3–MeOH gave compound 8 as a yellow oil (0.124 g, 77%); 1H NMR (CDCl3, 500 
MHz) δ 3.39 (4H, s), 3.28 (4H, s), 2.72-2.82 (6H, m), 2.63 (2H, t, J = 5.4 Hz), 1.39 (9H, s), 1.38 
(27H, s); 13C NMR (CDCl3, 500 MHz) δ 170.9, 170.7 (3C), 80.8 (4C), 55.9 (2C), 55.8 (2C), 52.4, 
52.3, 51.3, 47.0, 28.2 (3C), 28.1 (9C); HRMS (FAB) m/z calcd for C28H54N3O8 ([M+H]+): 560.3911, 
found 560.3910. 
4.1.3. Standard procedure for solid-phase peptide synthesis.  
Protected peptide-resins were manually constructed by Fmoc-based solid-phase peptide synthesis. 
t-Bu ester for Asp and Glu; 2,2,4,6,7-pentamethyldihydrobenzofurane-5-sulfonyl (Pbf) for Arg; 
t-Bu for Thr and Tyr; Boc for Lys and Trp; Trt for Cys were employed for side-chain protection. 
Fmoc-amino acids were coupled using three equivalents of reagents [Fmoc-amino acid, 
1,3-diisopropylcarbodiimide (DIC), and HOBt·H2O] to the free amino group in DMF for 1.5 h. 
Fmoc deprotection was performed by 20% (v/v) piperidine in DMF (2 × 1 min, 1 × 30 min). The 
protected peptide resin was treated with a cocktail of deprotection reagents. After removal of the 
resin by filtration, the filtrate was poured into ice-cold dry Et2O. The resulting powder was 
collected by centrifugation and washed with ice-cold dry Et2O. The crude peptide was dissolved in 
H2O, and the pH was adjusted to 8.0 with NH4OH for disulfide bond formation. After air-oxidation 
for 1 d, the crude product was purified by preparative HPLC on a Cosmosil 5C18-ARII preparative 
column (Nacalai Tesque, Kyoto, Japan; 20 × 250 mm, flow rate 10 mL/min) to afford the expected 
peptides. All peptides were characterized by MALDI-TOF-MS (AXIMA-CFR plus, Shimadzu, 
Kyoto, Japan) and the purity was calculated as >95% by HPLC on a Cosmosil 5C18-ARII 
analytical column (Nacalai Tesque, 4.6 × 250 mm, flow rate 1mL/min) at 220 nm absorbance.  
4.1.4. Preparation of DTPA- and DOTA-conjugated octreotides (19a,b).  
According to the procedure reported previously,18 (2-chloro)trityl chloride resin 15 (214 mg, 1.4 
mmol/g), Fmoc-Thr(t-Bu)-ol (345 mg, 0.9 mmol), and pyridine (0.145 mL, 1.8 mmol) were agitated 
for 21 h in dry CH2Cl2–DMF (1:1, 3.94 mL). The loading was determined by measuring the 290 nm 
UV absorption of the piperidine-treated sample (0.455 mmol/g). After the construction of the 
peptide chain (0.017 mmol scale) using a standard procedure, bromoacetic acid (23.6 mg, 0.17 
mmol) with DIC (0.026 mL, 0.17 mmol) in CH2Cl2 was reacted with resin 16 for 2 h at room 
temperature. The subsequent treatment of 17 with amines 8 (29.0 mg, 0.51 mmol) and 20 (26.3 mg, 
0.51 mmol) with (i-Pr)2NEt (0.009 mL, 0.51 mmol) in DMF for 12 h at room temperature provided 
18a and 18b, respectively. Cleavage and deprotection of 18a (72.5 mg) and 18b (73.8 mg) was 
achieved using a TFA/1,2-ethandithiol (EDT)/H2O (5 mL; 95:2.5:2.5) cocktail for 2 h at room 
temperature and by treatment with 1 M TMSBr-thioanisole/TFA in the presence of EDT/m-cresol 
(3.3 mL) for 2 h at 0 °C, respectively. After disulfide formation under air-oxidation conditions, the 
crude peptides were purified using the standard procedure, to afford the desired peptides 19a (8.2 
mg, 23%) and 19b (9.5 mg, 26%) as white powders. Compound 19a: MS (MALDI-TOF) m/z calcd 
for C63H89N13O19S2 ([M+H]+): 1395.6, found 1395.3. Compound 19b: MS (MALDI-TOF) m/z 
calcd for C65H93N14O17S2 ([M+H]+): 1405.6, found 1405.8. 
4.1.5. Preparation of DTPA-conjugated CXCR4 antagonists (26a-c).  
Protected peptide resins were manually constructed according to the standard procedure using 
NovaSyn TGR-resin 21 (96.2 mg, 0.025 mmol). 4-Methyltrityl (Mtt) group was employed for the 
protection of the D-Lys ε-amino group. The N-terminal amino group was acylated by treatment 
with Ac2O (0.012 mL, 0.125 mmol)/pyridine (0.020 mL, 0.250 mmol) for 1 h at room temperature 
for peptides 26a,b, and with 4-fluorobenzoic acid (17.5 mg, 0.125 mmol)/DIC (0.019 mL, 0.125 
mmol)/HOBt·H2O (19.2 mg, 0.125 mmol) for 1.5 h at room temperature for peptide 26c. 
Subsequently, the resin 22 was treated with CH2Cl2/1,1,1,3,3,3-hexafluoropropan-2-ol 
(HFIP)/trifluoroethanol (TFE)/triethylsilane (TES) [65:20:10:5; 5 mL] for 2 h at room temperature. 
The DTPA group was incorporated using the identical procedure employed for the synthesis of the 
octreotide derivative 19a. Treatment of the resins (25a: 178 mg, 25b: 165 mg, 25c: 162 mg) with a 
TFA/1,2-ethandithiol(EDT)/H2O (95:2.5:2.5; 5 mL) cocktail for 2 h at room temperature followed 
by air oxidation and purification provided the peptides 26a (14.6 mg, 15.4%), 26b (6.67 mg, 8.7%) 
and 26c (7.4 mg, 9.5%) as white powders. Compound 26a: MS (MALDI-TOF) m/z calcd for 
C106H165N38O28S2 ([M+H]+): 2482.2, found 2482.5. Compound 26b: MS (MALDI-TOF) m/z calcd 
for C106H165N36O28S2 ([M+H]+): 2454.2, found 2453.9. Comound 26c: MS (MALDI-TOF) m/z 
calcd for C111H166FN36O28S2 ([M+H]+): 2534.2, found 2533.8.  
4.1.6. Indium chelating for CXCR4 antagonist probes (27a-c).  
To a solution of peptides 26a-c (8 mM in 0.1N AcOH, 26a: 45.9 μL, 0.37 μmol; 26b: 48.4 μL, 
0.39 μmol; 26c: 48.8 μL, 0.39 μmol), InCl3 (1 M in 0.02N HCl, 50 μL) was added and the solution 
stirred for a further 30 min at room temperature. HPLC purification using a standard procedure 
provided the desired peptides 27a (0.43 mg, 36.7%), 27b (0.42 mg, 34.3%) and 27c (0.38 mg, 
30.3%) as white powders. Compound 27a: MS (MALDI-TOF) m/z calcd for C106H165InN38O28S2 
([M+H]+): 2597.1, found 2596.9. Compound 27b: MS (MALDI-TOF) m/z calcd for 
C106H165InN36O28S2 ([M+H]+): 2569.1, found 2569.1. Comopund 27c: MS (MALDI-TOF) m/z 
calcd for C111H166FInN36O28S2 ([M+H]+): 2649.1, found 2649.0.  
4.2. Evaluation of [125I]-SDF-1 binding and displacement. 
For ligand binding, the CXCR4 membrane was incubated with 0.5 nM of [125I]-SDF-1 and 
increasing concentrations of compounds 27a-c in binding buffer [50 mM HEPES (pH 7.4), 5 mM 
MgCl2, 1 mM CaCl2 and 0.1% BSA in H2O] for 1 h at room temperature. The reaction mixtures 
were filtered through GF/B filters (Perkin-Elmer, Wellesley, MA) pretreated with 0.1% 
polyethyleneimine. The filter plate was washed with wash buffer [50 mM HEPES (pH 7.4), 500 
mM NaCl and 0.1% BSA in H2O] and the bound radioactivity was measured by TopCount (Packard, 
Meriden, CT). Inhibitory activity of test compounds was determined based on the inhibition of 
[125I]-SDF-1 binding to the CXCR4 receptor (IC50).  
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Fig. 1  Structures of radionuclide chelating agents and the precursors. 
 
 
Scheme 1  (A) Synthetic scheme for the DTPA-conjugation reagent 10 prepared in our previous 
study; (b) synthetic plan for the DTPA-conjugated peptides in this study. Reagents: (a) CF3CO2Et; 
(B) BrCH2CO2t-Bu, (i-Pr)2NEt; (c) BrCH2CO2t-Bu, NaH; (d) NH2NH2, t-BuOH; (e) BrCH2CO2Bn, 
(i-Pr)2NEt; (f) H2, Pd/C; (g) DCC, HOSu. 
 
Scheme 2  Synthesis of DTPA precursor 8 via a global N-alkylation process using a Ns-protecting 
group. Reagents: (a) NsCl; (b) BrCH2CO2t-Bu, K2CO3; (c) HSCH2CO2H, LiOH. 
Scheme 3  Synthesis of DTPA- and DOTA-conjugated D-Phe-octreotides. Reagents: (a) 
Fmoc-based peptide synthesis; (b) BrCH2CO2H, DIC; (c) 8 for 18a, or 20 for 18b, (i-Pr)2NEt (d) 
TFA/H2O/1,2-ethanedithiol (EDT) (95:2.5:2.5) for 19a, 1M TMSBr, thioanisole/TFA, 
1,2-ethanedithiol, m-cresol for 19b; (e) NH4OH (air oxidation). 
Scheme 4  Site-specific In-DTPA labeling of CXCR4 antagonists and biological activity. 
Reagents: (a) Fmoc-based peptide synthesis; (b) CH2Cl2/1,1,1,3,3,3-hexafluoro-2-propanol 
(HFIP)/2,2,2-trifluoroethanol (TFE)/triethylsilane (TES) (65:20:10:5); (c) BrCH2CO2H, DIC; (d) 8, 
(i-Pr)2NEt; (e) TFA/H2O/EDT (95:2.5:2.5); (f) NH4OH (air oxidation); (g) InCl3. Abbreviations: 
Mtt: 4-methyltrityl; Cit: L-citrulline, Nal: L-3-(2-naphthyl)alanine, 4FBz: 4-fluorobenzoyl. 
 
